Bax inhibitor peptide V5 (0-50 μM) reduces cell death in STF-cMyc cells but not in NCI-H23 or SW620 cells. BIPV5 does not result in any significant effect on cell cycle arrest at the G2/M phase [1]. Bax inhibitor peptide V5 treatment upregulates expression of anti-apoptotic proteins Bcl-2 and XIAP by more than 3- and 11-fold and downregulates expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-κB-p65 by 10, 30, and nearly 50%, respectively [2].

In mice model, Bax inhibitor peptide V5 (100 μM) significantly improves islet function following isolation and improves islet graft function following transplantation [2].